Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 May 7;17(5):e83652.
doi: 10.7759/cureus.83652. eCollection 2025 May.

Development of Seborrheic Keratosis and Human Papillomavirus (HPV) Infection Following Four Months of Fingolimod Treatment in a Patient With Multiple Sclerosis: A Report of a Rare Case

Giorgi Mamardashvili  1 , Nazibrola Botchorishvili  2 , Gucha Kobaidze  2 , Marina Janelidze  2
Affiliations
Case Reports

Development of Seborrheic Keratosis and Human Papillomavirus (HPV) Infection Following Four Months of Fingolimod Treatment in a Patient With Multiple Sclerosis: A Report of a Rare Case

Giorgi Mamardashvili et al. Cureus. .

Abstract

Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system in young adults. Disease-modifying therapies (DMTs) for MS target different aspects of the immune system and have various safety profiles. Fingolimod is a DMT introduced for the treatment of MS. Cutaneous adverse events have been well described in patients treated with fingolimod. We present a clinical case of a patient with relapsing-remitting multiple sclerosis (RRMS) who developed multiple skin lesions after four months of treatment with fingolimod. Diagnosis of seborrheic keratosis, nevi, and papilloma was made clinically based on characteristic lesion morphology. Histologic confirmation was not performed, and human papillomavirus (HPV) DNA testing was positive. Rapid progression of cutaneous lesions prompted the switch to a different DMT, after which the lesions resolved completely within two months.

Keywords: disease-modifying therapy; fingolimod; hpv infection; relapsing-remitting multiple sclerosis; seborrheic keratosis.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. (a-c) Multiple papillomas and seborrheic keratoses on the neck; (d, e) seborrheic keratoses and nevi on the chest and abdomen; (f) genital warts.
See this image and copyright information in PMC

References

    1. Multiple sclerosis: pathogenesis and treatment. Loma I, Heyman R. Curr Neuropharmacol. 2011;9:409–416. - PMC - PubMed
    1. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. Weiner HL. J Neurol. 2008;255 Suppl 1:3–11. - PubMed
    1. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Chun J, Hartung HP. Clin Neuropharmacol. 2010;33:91–101. - PMC - PubMed
    1. Warts and all: fingolimod and unusual HPV-associated lesions. Triplett J, Kermode AG, Corbett A, Reddel SW. Mult Scler. 2019;25:1547–1550. - PubMed
    1. Two unexpected cases of rosacea during fingolimod therapy. Brusco S, Bertini M, Scavone C, Docimo R, Bisecco A, Capuano A, Gallo A. https://www.walshmedicalmedia.com/open-access/two-unexpected-cases-of-ro... J Pharmacovigil. 2018;6:4.

Publication types

LinkOut - more resources